[kc_row use_container=”yes” force=”no” column_align=”middle” video_mute=”no” _id=”784008″][kc_column width=”12/12″ video_mute=”no” _id=”208634″][kc_column_text]
ACR-COVID-19 Clinical Guidance Summary Patients with Rheumatic Diseases.pdf
Baricitinib as potential treatment for 2019-nCoV acute respiratory disease_32032529.pdf
Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury_32043983.pdf
Coronavirus disease 2019 (COVID-19) and anti-rheumatic drugs_32232552.pdf
COVID-19 – Considerations for the paediatric rheumatologist_32283324.pdf
COVID-19 consider cytokine storm syndromes and immunosuppression_32192578.pdf
COVID-19 infection and rheumatoid arthritis Faraway, so close_32205186.pdf
COVID19 The new challenge for rheumatologists_32207680.pdf
NICE_COVID-19 rapid guideline: rheumatological autoimmune, inflammatory and metabolic bone disorders
Role of immunosuppressive therapy in rheumatic diseases concurrent with covid-19_32295789.pdf
The COVID‐19 outbreak and rheumatologic skin diseases-32237261.pdf
The Rheumatologist’s Role in Covid-19_32209661.pdf
Urology practice during COVID-19 pandemic_32202401.pdf
What is the true incidence of COVID-19 in patients with rheumatic diseases_32321723.pdf
[/kc_column_text][/kc_column][/kc_row]